The TP508 Solution for Respiratory Failure (ARDS)
Respiratory Failure (ARDS)
A single injection of TP508 24 hours after SARS-CoV-2 infection almost completely blocks the viral-induced cytokine storm including upregulation of IL6 and TNFa) in animals expressing the human ACE2 receptor. Thus, TP508 reduces inflammation which mitigates vascular effects of SARS-CoV-2 leading to disease progression, allowing for earlier patient recovery.
Other preclinical studies show that TP508 can prevent vascular changes that are associated with COVID-19 progression.
- TP508 attenuates neuroinflammation and blood barrier changes induced by radiotherapy and traumatic brain injury.
- TP508 reverses ischemic effects in the heart following acute myocardial infarct
- TP508 reduces radiation-induced coagulopathy and hemorrhage in brain, heart and lungs to prevent multiple organ failure.
TP508 is as an injectable drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS induced by viral infection (COVID19) or nuclear radiation. TP508 also activates stem cells to regenerate tissues and restore function. Because TP508 can affect cellular processes involved in ARDS progression at multiple points, it has the advantage of potentially showing efficacy where previous candidate drugs have failed